摘要:
Die Erfindung liegt auf dem Gebiet der in vitro-Diagnostik und betrifft ein Verfahren zur quantitativen Bestimmung von therapeutischen TNF-alpha Inhibitoren.
摘要:
An antibody comprising an antigen recognition domain that binds specifically the extracellular domain of TNF-related apoptosis-inducing ligand (TRAIL) between amino acids 95-155 and/or amino acids 190-210 is disclosed. Uses thereof are also disclosed.
摘要:
Growth Factors are groups of proteins, having an important role in the regulation of cellular processes. Cytokines are Subtypes of Growth Factors. In pathological condition Cytokines have an important role in Cancer pathogenesis and management of cancer. Targeted therapies are currently the focus of anticancer drug development. They are beneficial for many cancer types, including lung, colorectal, breast, lymphoma and leukaemia. The cancer-associated Cytokine-Network may represent new ways for cancer therapy. Speciflc-Targeted Therapv/Principle: Cytokine induces the synthesis of other Cytokine(s). The inducer and the induced Cytokine(s) have the same (similar) pathological effects. The antibody will be used against onlv the inducer-cytokine, leading to the abolishment of the pathological effect(s). Mapping of Cvtokines will be carried out: Tumour Necrosis Factors (α, β), Interleukin-1 (α, β), Interleukin-6, Interleukin- 10, Interleukin- 12, Interleukin- 17, Interleukin-23 and Vascular Endothelial Growth Factor.
摘要:
Described are methods of treating or preventing an inflammatory disease or condition caused by excessive expression, secretion, or concentration of alpha synuclein. The methods comprise administering compositions that reduce the effective concentration of alpha-synuclein present in the surrounding tissues. In addition, the invention encompasses methods of inhibiting alpha-synuclein interaction with CD11b, comprising administering an agent that binds to alpha-synuclein to prevent binding productively to the integrin CD11b, or administering an active agent that interacts with CD11b on an immune cell to prevent alpha-synuclein from directing chemotaxis of that cell. In addition, the invention discloses a method of identifying an individual with a condition amenable to treatment targeting alpha-synuclein CD11b interaction.
摘要:
The present invention relates to an in vitro method for the prognostic of a subject affected by a demyelinating disease comprising detecting and quantifying the level of at least one of CCL19, IL-15, ENA78 and/or TRAIL in a biological fluid from the subject. The invention also relates to the treatment of a subject affected by a demyelinating disease comprising the use of at least one modulator of CCL19, IL-15, ENA78 and/or TRAIL.
摘要:
Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-binding proteins, vectors containing the disclosed polynucleotides, and cells that have been genetically engineered to express the polynucleotide are also provided. Methods of using the multifunctional antigen-binding proteins are disclosed.
摘要:
Provided herein, are matrices and methods for the stabilization of proteins and nucleic acids. The stabilized proteins and nucleic acids described herein can be in a sample taken from a subject and can be subsequently stabilized and stored on the matrix. An analyte of interest can be concentrated and eluted for analysis from this sample. The stabilized proteins and nucleic acids described herein can be components of a sample preparation reagent, and the reagent is stored on the matrix and hydration of the matrix with a sample can result in a reaction occurring.
摘要:
The present disclosure provides methods for generating myokines in vitro and compositions comprising myokines. Such compositions may be used for treatment of diseases such as cancer and fatty liver disease.
摘要:
Provided are methods, kits, and devices for diagnosing and monitoring dry eye disease in a subject. The methods comprise measuring in a sample from the subject a level of at least one biomarker selected from the group consisting of TNF α, IL-4, IL-3, IL-10, GM-CSF, IL-13, IL-5, and IL-9, and/or any derivative, fragment, or precursor of the biomarkers.
摘要:
The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.